drug

cosibelimab

Marketedupdated 3mo ago

by Checkpoint Therapeutics Inc

Approved

community read0 votes

🐶 often sniffed alongside

top 3

Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for head and neck squamous cell carcinoma and 2 investigational indications.

all catalysts(2)

approval · 2

UNLOXCYT (COSIBELIMAB-IPDL) — FDA approval

UNLOXCYT (COSIBELIMAB-IPDL) — FDA approval

cosibelimab

→

Trials studying cosibelimab

phase4Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancynot yet recruitingn=80
phase3Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLCterminatedn=25
phase1Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancersactive not recruitingn=272

News(0)

no news has mentioned this drug yet

Data sources

openFDA · ClinicalTrials.gov

last refreshed 25m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

cosibelimab

Marketedupdated 3mo ago

by Checkpoint Therapeutics Inc

Approved

community read0 votes

🐶 often sniffed alongside

top 3

Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for head and neck squamous cell carcinoma and 2 investigational indications.